Regeneron - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
REGN
Regeneron is a biopharmaceutical company that harmonizes biology and technology to develop life-changing medicines. Its focus spans biologics and genetic medicines across oncology/hematology, inflammatory diseases, neuroscience, respiratory and other serious conditions, with operations and clinical development rooted in the United States and global collaborations. The company emphasizes research and development, clinical trials, and a commitment to responsible practices and patient access. Headquartered in the U.S., Regeneron positions itself at the intersection of science and medicine to bring therapies to patients worldwide.
#JPM26: Regeneron, Lilly, Summit on Rivals Crowding Into Same Targets
BrightInsight Secures $13M Funding Round
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Hiring Outlook: February Brings First YOY Job Increase Since 2022
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Gene Therapy Reduces Geographic Atrophy Lesion Growth
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
2025 Novel Large Molecule FDA Drug Approvals
An Opinionated Take on NEJM Highlights for Q1 of 2026
AbbVie Turbocharges Its US Investment Promise to $100bn
The Next Wave of Biotech Growth — a Perspective
AbbVie, Gubra Post Obesity Data; Regeneron Obesity Drug Succeeds in China
Sanofi Plans Amlitelimab Dermatitis Filing After New Readout
Novartis' Oral BTK Drug Moves the Needle in CINDU
J&J Jumps on the MFN Pricing Train
Sanofi Linked to Takeover Bid for Ocular Therapeutix
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
FUJIFILM Irvine Scientific Becomes FUJIFILM Biosciences
FDA Starts Review of Regeneron's Drug for Rare Disease FOP
Amgen Gives up on Its Once-Prized Eczema Drug
COPD Patients Will Get Access to Dupixent via NHS
A Clearer Path to Relief: Sinusitis Treatments on the Way
The Top 12 Companies Hiring in Biopharma Now
No recent deals for this company.
